Education for your patients.

Novo Nordisk helps you support your patients with resources and tools for success, right from the start. Educational materials available to download, share, or have delivered to your office.

  • Patient Brochure

    This brochure describes the key attributes of Novoeight®, with additional information on patient support and product support.

  • Reconstitution Video

    This patient-friendly educational tool shows both patients and HCPs how to correctly prepare Novoeight® for infusion.

  • Conversation Starter

    This 2-sided, 8-panel print piece is designed to help patients evaluate their treatment needs and show them how Novoeight® can meet those needs. 

  • Travel Kit

    Novoeight® is ready to go when he is. The stylish and customizable travel kit makes it possible for him to take treatment with him.

  • Demonstration Kit

    This kit demonstrates the compact storage size and portability of Novoeight®, and helps you show patients how quick it is to reconstitute a dose of Novoeight®. Patients may practice mixing a dose to become familiar with the process before leaving your office. Please see full Prescribing Information for complete Instructions for Use.

Education for you.

Let us help you educate your patients with bleeding disorders, through our comprehensive selection of professional educational materials.

Patient advocacy groups.

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.